Patents Assigned to Alseres Pharmaceuticals, Inc.
-
Patent number: 9757483Abstract: A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [123I]-2?-carbomethoxy-3?-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.Type: GrantFiled: October 17, 2014Date of Patent: September 12, 2017Assignee: Alseres Pharmaceuticals, Inc.Inventors: Chris Sterzinger, Cara Ferreira, David Leyh, Richard Thorn
-
Patent number: 8986653Abstract: A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [123I]-2?-carbomethoxy-3?-(4-flurophenyl)-N-(3-iodo-E-allyl)nortropane.Type: GrantFiled: October 2, 2013Date of Patent: March 24, 2015Assignee: Alseres Pharmaceuticals, Inc.Inventors: Chris Sterzinger, Cara Ferreira, David Leyh, Richard Thorn
-
Publication number: 20140037544Abstract: A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [123I]-2?-carbomethoxy-3?-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.Type: ApplicationFiled: October 2, 2013Publication date: February 6, 2014Applicant: Alseres Pharmaceuticals, Inc.Inventors: Chris Sterzinger, Cara Ferreira, David Leyh, Richard Thorn
-
Patent number: 8574545Abstract: A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [123I]-2?-carbomethoxy-3?-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.Type: GrantFiled: March 24, 2009Date of Patent: November 5, 2013Assignee: Alseres Pharmaceuticals, Inc.Inventors: Chris Sterzinger, Cara Ferreira, David Leyh, Richard Thorn
-
Patent number: 8133861Abstract: Methods for modulating the axonal outgrowth of central nervous system neurons are provided by means of internalized purine administration such as by intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, and intrapleural administration. The methods are noted for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, traumatic brain injury, cerebral aneurism, spinal cord injury and the like).Type: GrantFiled: February 26, 2009Date of Patent: March 13, 2012Assignee: Alseres Pharmaceuticals, Inc.Inventors: Noel James Cusack, Mark R. Hurtt, Richard M. Thorn
-
Patent number: 8084018Abstract: Presented is a method for assessing dopamine transporter levels in a selected area of a subject's central nervous system by SPECT imaging comprising administering an injection of a labeled dopamine transporter ligand at approximately the time the subject is positioned for SPECT imaging and initiating a SPECT acquisition for a duration of about 30 minutes commencing at about 15 minutes after administration of labeled dopamine transporter ligand; and assessing, based on said SPECT acquisition, the amount of labeled dopamine transporter ligand that is bound to dopamine transporter.Type: GrantFiled: October 31, 2007Date of Patent: December 27, 2011Assignee: Alseres Pharmaceuticals, Inc.Inventor: Mark Hurtt
-
Publication number: 20100312105Abstract: A method of diagnosing Lewy Body Dementia in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where a lowered level of dopamine transporter in the patient is indicative of Lewy Body Dementia. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.Type: ApplicationFiled: October 29, 2008Publication date: December 9, 2010Applicant: ALSERES PHARMACEUTICALS, INC.Inventor: Mark Hurtt
-
Publication number: 20090297446Abstract: A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [123I]-2?-carbomethoxy-3?-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.Type: ApplicationFiled: March 24, 2009Publication date: December 3, 2009Applicant: Alseres Pharmaceuticals, Inc.Inventors: Chris Sterzinger, Cara Ferreira, David Leyh, Richard Thorn
-
Publication number: 20090252712Abstract: Methods of treating bone disorders in a subject in need thereof by administering to said subject a therapeutically effective amount of a Rho antagonist are disclosed.Type: ApplicationFiled: March 9, 2009Publication date: October 8, 2009Applicant: Alseres Pharmaceuticals, Inc.Inventors: Noel James Cusack, Jon Scott Munzer
-
Publication number: 20090221521Abstract: Methods for modulating the axonal outgrowth of central nervous system neurons are provided by means of internalized purine administration such as by intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, and intrapleural administration. The methods are noted for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, traumatic brain injury, cerebral aneurism, spinal cord injury and the like).Type: ApplicationFiled: February 26, 2009Publication date: September 3, 2009Applicant: Alseres Pharmaceuticals, Inc.Inventors: Mark R. Hurtt, Noel James Cusack, Richard M. Thorn
-
Publication number: 20090156491Abstract: The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homolgous to amino acid residues 130-137 or 132-139 of human troponin subunit I.Type: ApplicationFiled: October 20, 2008Publication date: June 18, 2009Applicants: CHILDREN'S MEDICAL CENTER CORPORATION, INC., ALSERES PHARMACEUTICALS, INC.Inventors: Richard M. Thorn, Marc E. Lanser, Marsha A. Moses, Dmitri G. Wiederschain
-
Patent number: 7452866Abstract: The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homologous to amino acid residues 130-137 or 132-139 of human troponin subunit I.Type: GrantFiled: January 5, 2006Date of Patent: November 18, 2008Assignees: Children's Medical Center Corporation, Alseres Pharmaceuticals, Inc.Inventors: Richard M. Thorn, Mark A. Lanser, Marsha A. Moses, Dmitri G. Wiederschain